Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 4/20 | 0.38 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7593158 | 0.70 | OPRM1 (0.37) | — | |
| SCHEMBL7865778 | 0.69 | SMN1; SMN2 (0.38) | SMN1; SMN2NOS3NOS1NOS2ALOX15 | |
| SCHEMBL11891933 | 0.67 | HRH3 (0.52) | SMN1; SMN2ALOX15KDM4EALDH1A1MAPT | |
| SCHEMBL27727944 | 0.64 | CNR1 (0.39) | KDM4EALDH1A1MAPT | |
| SCHEMBL12126259 | 0.64 | ALDH1A1 (0.42) | SMN1; SMN2KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL18775271 | 0.62 | LMNA (0.59) | SMN1; SMN2NOS3NOS1NOS2KDM4E | |
| SCHEMBL18753614 | 0.62 | LMNA (0.58) | SMN1; SMN2KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL15417767 | 0.60 | TDP1 (0.56) | SMN1; SMN2ALDH1A1MAPTLMNAGAA | |
| SCHEMBL19710682 | 0.60 | GAA (0.44) | SMN1; SMN2KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL18773675 | 0.59 | MC4R (0.53) | KDM4EALDH1A1MAPTLMNAMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | NEUROGEN CORPORATION | 2002-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | CRH, CRHR1, CRHR2 | SMN1; SMN2 4248/4885NOS3 3184/4885NOS1 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.